Product details
Background：Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.
• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929
• The diverse functions of the PD1 inhibitory pathway., PMID:28990585
• PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996
• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
• PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007
• Overcoming T cell exhaustion in infection and cancer., PMID:25797516
• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727
• Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275
• PD-L1., PMID:29097600
